Phillip Darcy

A histone deacetylase inhibitor, panobinostat, enhances chimeric receptor antigen T cell anti-tumor effect against pancreatic cancer.

Aesha I Ali, Minyu Wang, Bianca von Scheidt, Pilar M Dominguez, Aaron J Harrison, Daniela GM Tantalo, Jian Kang, Amanda J Oliver, Jack D Chan, Xin Du, Yuchen Bai, Belinda Lee, Ricky W Johnstone, Phillip K Darcy, Michael H Kershaw, Clare Y Slaney

Journal article  |  2021  |  Clin Cancer Res

PURPOSE: Here we describe a combination chimeric antigen receptor (CAR) T cell therapy that eradicated the majority of tumors in t..

Myeloma natural killer cells are exhausted and have impaired regulation of activation

Criselle D'Souza, Simon P Keam, Han Xian Aw Yeang, Michael Neeson, Kelden Richardson, Andy K Hsu, Rachael Canfield, Natalie Bezman, Michael Robbins, Hang Quach, David S Ritchie, Simon J Harrison, Joseph A Trapani, H Miles Prince, Paul A Beavis, Phillip K Darcy, Paul J Neeson

Journal article  |  2021  |  HAEMATOLOGICA

Not available.

Early-phenotype CAR-T cells for the treatment of pediatric cancers.

D Meyran, RL Terry, JJ Zhu, M Haber, DS Ziegler, PG Ekert, JA Trapani, PK Darcy, PJ Neeson

Journal article  |  2021  |  Ann Oncol

Chimeric antigen receptor (CAR)-T-cell therapy is a promising approach for the treatment of childhood cancers, particularly high-r..

MAIT cells regulate NK cell-mediated tumor immunity

Emma Petley, Hui-Fern Koay, Melissa A Henderson, Kevin Sek, Kirsten L Todd, Simon P Keam, Junyun Lai, Imran G House, Jasmine Li, Magnus Zethoven, Amanda XY Chen, Amanda J Oliver, Jessica Michie, Andrew J Freeman, Lauren Giuffrida, Jack D Chan, Angela Pizzolla, Jeffrey YW Mak, Timothy R McCulloch, Fernando Souza-Fonseca-Guimaraes, et al.

Journal article  |  2021  |  NATURE COMMUNICATIONS

The function of MR1-restricted mucosal-associated invariant T (MAIT) cells in tumor immunity is unclear. Here we show that MAIT ce..

CRISPR/Cas9 mediated deletion of the adenosine A2A receptor enhances CAR T cell efficacy

Lauren Giuffrida, Kevin Sek, Melissa A Henderson, Junyun Lai, Amanda XY Chen, Deborah Meyran, Kirsten L Todd, Emma Petley, Sherly Mardiana, Christina Molck, Gregory D Stewart, Benjamin J Solomon, Ian A Parish, Paul J Neeson, Simon J Harrison, Lev M Kats, Imran G House, Phillip K Darcy, Paul A Beavis

Journal article  |  2021  |  NATURE COMMUNICATIONS

Adenosine is an immunosuppressive factor that limits anti-tumor immunity through the suppression of multiple immune subsets includ..

Preclinical Evidence of the Efficacy of Lewis Y Car T Cells in Patient-Derived Models of Prostate Cancer

Gail Petuna Risbridger, Laura Helen Porter, Joe Zhu, David Byrne, Natalie Lister, Arun Azad, Michael Hofman, Ian Vela, Renea A Taylor, Paul Neeson, Phil Darcy, Joseph Trapani

Conference Proceedings  |  2021  |  Journal of the Endocrine Society

Abstract Chimeric antigen receptor T (CAR T) cell therapy is an adoptive immunotherapy that has led to new treatmen..

Cellular networks controlling T cell persistence in adoptive cell therapy

Jack D Chan, Junyun Lai, Clare Y Slaney, Axel Kallies, Paul A Beavis, Phillip K Darcy

Journal article  |  2021  |  NATURE REVIEWS IMMUNOLOGY

The antitumour activity of endogenous or adoptively transferred tumour-specific T cells is highly dependent on their differentiati..

Tucatinib favourably modulates the immune microenvironment and synergises with anti-PD1 therapy in a trastuzumab resistant HER2 murine model

Ran Li, Sneha Sant, Emmaline Brown, Franco Caramia, Ann Byrne, Kylie Clarke, Michael Neeson, Paul J Neeson, Phillip K Darcy, Scott Peterson, Sherene Loi

Conference Proceedings  |  2021  |  CANCER RESEARCH

Toward precision immunotherapy using multiplex immunohistochemistry and in silico methods to define the tumor immune microenvironment

Samuel S Widodo, Ryan A Hutchinson, Yitong Fang, Stefano Mangiola, Paul J Neeson, Phillip K Darcy, Alexander D Barrow, Christopher M Hovens, Marija Dinevska, Stanley S Stylli, Theo Mantamadiotis

Journal article  |  2021  |  CANCER IMMUNOLOGY IMMUNOTHERAPY

Recent developments in cancer immunotherapy promise better outcomes for cancer patients, although clinical trials for difficult to..

Generating CAR T cells from tumor-infiltrating lymphocytes.

Jane K Mills, Melissa A Henderson, Lauren Giuffrida, Pasquale Petrone, Jennifer A Westwood, Phillip K Darcy, Paul J Neeson, Michael H Kershaw, David E Gyorki

Journal article  |  2021  |  Ther Adv Vaccines Immunother

Background: Tumor-infiltrating lymphocytes (TILs) and chimeric antigen receptor (CAR) T-cell therapies have demonstrated promising..